News | Artificial Intelligence | March 02, 2023

Qure.ai and Therapixel have announced a new partnership whereby Qure.ai will be a global distributor for Therapixel’s MammoScreen to improve early breast cancer detection.

Qure.ai and Therapixel have announced a new partnership whereby Qure.ai will be a global distributor for Therapixel’s MammoScreen.

Qure.ai and Therapixel have announced a new partnership whereby Qure.ai will be a global distributor for Therapixel’s MammoScreen. Photo courtesy Therapixel-Mammoscreen.


March 2, 2023 — Qure.ai, a London-based medical Artificial Intelligence (AI) imaging company, has announced a new partnership with Therapixel, a French firm that uses AI to improve the early breast cancer detection, whereby Qure.ai will be a global distributor for Therapixel’s MammoScreen. In a statement issued by Qure.ai, through the partnership, Qure.ai and Therapixel aim to improve the accuracy and efficiency of breast cancer detection, by enabling radiologists to read large numbers of screening mammograms in 2D and 3D more confidently.

According to recent studies, as noted in a statement issued on the partnership, MammoScreen enabled radiologists of all experience levels to significantly improve their performance regarding the number of cancers detected and reading time. As a result, noted the company statement, the partnership between Qure.ai and Therapixel will benefit healthcare providers and patients globally with more accurate and efficient detection of breast cancer, ultimately leading to earlier diagnosis and better outcomes.

“Qure.ai is breaking new ground by bringing a fellow radiology AI provider on board for the first time in our history,” said Prashant Warier, CEO and Co-Founder of Qure.ai. Warier noted the collaboration builds on the company’s global distribution networks, opening a pipeline for future partnerships.

Matthieu Leclerc-Chalvet, CEO of Therapixel, added, “We are excited to partner with Qure.ai and expand the reach of MammoScreen across the globe,” said Matthieu Leclerc-Chalvet, CEO of Therapixel.

The update also noted that both less experienced and expert radiologists can achieve a high detection rate and improve their reading time with MammoScreen. Qure.ai offers a comprehensive imaging AI portfolio globally, covering lung and breast cancer, among other disease areas. The portfolio now also covers abnormality detection across Chest X-rays, Chest CTs, Head CTs, Musculoskeletal X-rays, and Breast Mammograms, allowing these cutting-edge AI solutions assist radiologists in faster and earlier diagnosis across different healthcare workflows and geographies.

Qure.ai recently announced (see related coverage below) it has been awarded CE Class IIb certification for medical devices under the European Union Medical Device Regulation (Regulation (EU) 2017/745) (EU-MDR).

The companies will be participating in the 2023 European Congress of Radiology (ECR) being held March 1-5 in Vienna, Austria. For its part, qure.ai reports that the company launched an AI playbook with CaritasKlinikum Saarbrücken, to provide European clinicians and radiologists with a helpful guide to understanding the business case for AI in radiology. Additionally, the company hosted a panel discussion, “AI Sparking the Cycle of Change” during the global conference. 

For more information: 

https://qure.ai/

https://www.therapixel.com

Related content:

Qure.ai Awarded EU MDR Certification for Its AI solutions

Therapixel Releases A New Version Of MammoScreen


Related Content

News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
News | Lung Imaging

September 26, 2023 — In a study of more than 2,000 chest X-rays, radiologists outperformed AI in accurately identifying ...

Time September 26, 2023
arrow
News | Point-of-Care Ultrasound (POCUS)

September 26, 2023 — Exo (pronounced “echo”), a medical imaging software and device company, today unveiled a category ...

Time September 26, 2023
arrow
News | Mammography

September 26, 2023 — Artificial intelligence(AI) and machine learning tools have received a lot of attention recently ...

Time September 26, 2023
arrow
News | Mammography

September 22, 2023 — Hologic Inc. and Bayer announced an international partnership to deliver contrast-enhanced ...

Time September 22, 2023
arrow
News | Digital Pathology

September 22, 2023 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time September 22, 2023
arrow
Feature | Breast Imaging | By Susan Harvey, MD, FSBI

In countries with organized screening programs, regular breast cancer screening has been a crucial tool in the clinician ...

Time September 22, 2023
arrow
Feature | Artificial Intelligence | By Melinda Taschetta-Millane

Jesse Ehrenfeld, MD, MPh, FAMIA, FASA, FCPP, president of the American Medical Association (AMA), addressed the topic of ...

Time September 22, 2023
arrow
Feature | Ultrasound Imaging | By Mustafa Hassan, PhD

Handheld ultrasound has not yet reached mainstream adoption, but the market is still forecast to reach over $500 million ...

Time September 20, 2023
arrow
News | Artificial Intelligence

September 20, 2023 — Medical imaging artificial intelligence (AI) company Annalise.ai has announced that the results ...

Time September 20, 2023
arrow
Subscribe Now